Vaxcyte (PCVX) Change in Account Payables (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Change in Account Payables data on file, last reported at -$269000.0 in Q1 2026.

• On a quarterly basis, Change in Account Payables rose 99.08% year-over-year to -$269000.0 in Q1 2026; TTM through Mar 2026 was $48.8 million, a 19542.23% increase from a year earlier, with the FY2025 full-year figure at $19.9 million, down 42.44% from the prior year.
• Change in Account Payables for Q1 2026 stood at -$269000.0, down from $21.7 million in the prior quarter.
• Over the last five years, Change in Account Payables for PCVX reached as high as $31.3 million in Q4 2024 and fell as low as -$29.2 million in Q1 2025.
• Historically, Change in Account Payables has averaged $4.0 million across 5 years, with a median of $2.7 million in 2022.
• Across the five-year window, Change in Account Payables soared 1097.55% in 2024 and sank 614.16% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at $3.5 million in 2022, then soared by 86.66% to $6.5 million in 2023, then surged by 383.24% to $31.3 million in 2024, then plunged by 30.8% to $21.7 million in 2025, then slumped by 101.24% to -$269000.0 in 2026.
• Per Business Quant data, the three most recent Change in Account Payables figures were -$269000.0 in Q1 2026, $21.7 million in Q4 2025, and $17.9 million in Q3 2025.